Hansa Biopharma AB (OSTO:HNSA)
kr 42.46 0.62 (1.48%) Market Cap: 2.78 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 73/100

Hansa Biopharma AB Redeye Orphan Drugs Event - Corporate Call Transcript

Apr 28, 2021 / NTS GMT
Release Date Price: kr171.8 (+0.17%)
Niklas Elmhammer
Redeye AB, Research Division - Research Analyst

And next up is Hansa Biopharma, and we will be joined by speaker, Klaus Sindahl, Head of Investor Relations.

Klaus Sindahl;publ;Head of IR
Hansa Biopharma AB

()-

Good morning, and thank you so much for your interest in Hansa Biopharma. Can you hear me?

Niklas Elmhammer
Redeye AB, Research Division - Research Analyst

Yes, absolutely. So please go ahead.

Klaus Sindahl;publ;Head of IR
Hansa Biopharma AB

()-

Okay. Yes. Yes. So my name is Klaus Sindahl, and I'm Head of Investor Relations here at Hansa. And I'm very excited to come here and present Hansa to this orphan drug event. So before I continue, I just need to briefly show you this slide on our forward-looking statements.

So Hansa Biopharma has now progressed into a commercial stage biopharmaceutical company, and we have a broad clinical pipeline in transplantation and in autoimmune

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot